Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard M. Stone is active.

Publication


Featured researches published by Richard M. Stone.


Blood | 2000

Report of an international working group to standardize response criteria for myelodysplastic syndromes

Bruce D. Cheson; John M. Bennett; Hagop M. Kantarjian; A. Pinto; Charles A. Schiffer; Stephen D. Nimer; B Lowenberg; M. Beran; T. M. De Witte; Richard M. Stone; Moshe Mittelman; Guillermo Sanz; Pierre W. Wijermans; Stacey M. Gore; Peter L. Greenberg


Archive | 2003

Acute Myeloid Leukemia in Adults

Charles A. Schiffer; Richard M. Stone


Blood | 2001

Myelodysplastic syndromes standardized response criteria: further definition.

Bruce D. Cheson; John M. Bennett; Hagop M. Kantarjian; Charles A. Schiffer; Stephen D. Nimer; B Lowenberg; Richard M. Stone; Moshe Mittelman; Guillermo Sanz; Pierre W. Wijermans; Peter L. Greenberg


Archive | 2003

Presenting Signs and Symptoms

Charles A. Schiffer; Richard M. Stone


Stem/Initiating Cells in Hematologic Malignancies | 2017

Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs

Julia Etchin; Alla Berezovskaya; Amy Saur Conway; Ilene Galinsky; Richard M. Stone; Erkan Baloglu; William Senapedis; Yosef Landesman; Michael Kauffman; Sharon Shacham; Jean Cy Wang; A. Thomas Look


Chemical Biology | 2017

Abstract PR04: Degradation of leukemia oncogenes: A novel approach to therapy of leukemia

Sara J. Buhrlage; Ellen Weisberg; Ilaria Lamberto; Jing Yang; Nathan J. Schauer; Martin Sattler; Atushi Nonami; Amanda L. Christie; David M. Weinstock; Stella Ritorto; Virginia DeCesare; Matthias Trost; Richard M. Stone; Nathanael S. Gray; James D. Griffin


Archive | 2013

with standard-dose cytarabine a randomized trial comparing mitoxantrone and intermediate-dose cytarabine Postremission therapy in older patients with de novo acute myeloid leukemia:

Charles A. Schiffer; Edward J. Lee; Joseph O. Moore; Bayard L. Powell; Maria R. Baer; Clara D. Bloomfield; Richard M. Stone; Deborah T. Berg; Stephen L. George; Richard K. Dodge; Paolo Alberto Paciucci


Archive | 2013

leukemia Endpoints to establish the efficacy of new agents in the treatment of acute

Nancy S. Scher; Franklin O. Smith; Richard M. Stone; Martin S. Tallman; Stephen J. Forman; Richard A. Larson; Stephanie J. Lee; Sharon B. Murphy; Susan O'Brien; R. Appelbaum; Daniel Rosenblum; Robert J. Arceci; William L. Carroll; Philip P. Breitfeld


Archive | 2013

respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3

Jennifer J. Clark; D. Gary Gilliland; James D. Griffin; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A. Fox; Donna Neuberg; Richard M. Stone; Daniel J. DeAngelo; Ilene Galinsky; E. Estey; Stephen D. Nimer


Archive | 2013

hematologic malignancies After chronic myelogenous leukemia: tyrosine kinase inhibitors in other

Martha Wadleigh; Daniel J. DeAngelo; James D. Griffin; Richard M. Stone

Collaboration


Dive into the Richard M. Stone's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian J. Druker

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard A. Larson

University of Tennessee Health Science Center

View shared research outputs
Top Co-Authors

Avatar

Hagop M. Kantarjian

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Stephen D. Nimer

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

James D. Griffin

State University of New York Upstate Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge